|
Carbimazole
resources
DRUG INFO
Carbimazole
Drug Name:
Carbimazole
|
|
|
Indication: For the treatment of hyperthyroidism; Thyrotoxicosis; It is also used to prepare patients for thyroidectomy.
Pharmacology:
Mechanism Of Action: Carbimazole is an aitithyroid agent that decreases the uptake and concentration of inorganic iodine by thyroid, it also reduces the formation of di-iodotyrosine and thyroxine.
Drug Category: Antithyroid Agents; ATC:H03BB01
Brand Names/Synonyms: Athyromazole; Atirozidina; Basolest; CG1; Carbethoxymethimazole; Carbimazol; Carbimazol Spofa; Carbimazol [Inn-Spanish, French]; Carbimazole; Carbimazole [Ban:Dcf:Inn]; Carbimazolum [Inn-Latin]; Carbinazole; Carbotiroid; Mertiran; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Neomercazole; Tyrazol
Dosage Forms: Tablet
Absorption: Not Available
Interactions: Interactions for Carbimazole:
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect
of Carbimazole.
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the
dosage may be necessary when patient becomes euthyroid.
Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days
after sudden withdrawal of Carbimazole.
Patient's response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin
time and an adjustment of anticoagulant dosage are recommended
Chemical IUPAC Name: ethyl 3-methyl-2-sulfanylidene-1,3-dihydroimidazole-1-carboxylate
Chemical Formula: C7H10N2O2S
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00503
CAS Registry Number: 22232-54-8
| | |
